A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
about
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesReview: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?Juvenile Idiopathic Arthritis: Diagnosis and Treatment2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening aTreatment of adult-onset Still's disease: a reviewRandomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.The development and assessment of biological treatments for children.An expanding role for interleukin-1 blockade from gout to cancer.Current medical treatments for juvenile idiopathic arthritis.Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis.Is Still's Disease an Autoinflammatory Syndrome?Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity.Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.Update on the treatment of juvenile idiopathic arthritisThe Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study.Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy.Treating inflammation by blocking interleukin-1 in humans.How not to miss autoinflammatory diseases masquerading as urticaria.Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.Update on biologicals for treatment of juvenile idiopathic arthritis.Canakinumab in pediatric rheumatic diseases.Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis.Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis.Association of NLRP3 and CARD8 genetic polymorphisms with juvenile idiopathic arthritis in a Taiwanese population.Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment.Cytokine networking of innate immunity cells: a potential target of therapy.Canakinumab for the treatment of systemic juvenile idiopathic arthritis.Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options.Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis.Treatment in juvenile rheumatoid arthritis and new treatment options.Novel treatment options for juvenile idiopathic arthritis.Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms.A Practical Approach to Juvenile Dermatomyositis and Juvenile Scleroderma.A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis.Canakinumab for the treatment of TNF-receptor associated periodic syndrome.
P2860
Q26799747-1791B840-7357-48CE-9F05-59C7CB5819EDQ27002805-CF46E07F-2DDD-480F-AFAF-C11CD3551E03Q28079246-EA904FD9-B058-4EEB-9233-1116F433A25EQ33613293-89E600CD-43BE-4AA7-9923-E46C705C301CQ34043097-8854E9EF-55AB-430C-8521-41E8C2CBD622Q35041117-202556D9-9E68-42FB-B7F5-4CCCF7D1E7EDQ35135936-CCCEBB7F-E552-4D4E-ACB6-58148E03D918Q35219001-FD3B7253-2AED-4D6F-80D1-937A1ABEE6CAQ35294398-525E3A73-AF57-40F2-B8BF-140EB55B9DDBQ35766646-53F81C47-99DF-45F9-A201-21E6DF2FB2DCQ35955190-46138151-081E-492A-8011-495D9B5005EFQ36304070-4A0868B2-B0B2-4736-ACF8-29B96B4D0A4CQ36816872-AC103249-E97A-4F31-9B0A-DF4BA5BDCF4DQ36903288-781FA4E9-5930-4362-BEFB-423148CEFFD2Q37060351-DB7664CB-D52C-4F23-AF77-7C850A98E5C7Q37270409-C90D6DE0-B0FF-4C70-B0E7-1E96DF6518E1Q37320554-8D212217-1AA6-4EE2-A7B9-3C1898B7C558Q37361075-8F5BC82F-C12E-4279-9FE2-D94E08CFD35DQ37602644-7134BBA4-319C-49C4-9F24-BCE1DA38D608Q37636664-A89774AE-42FB-4598-9BB2-A5DB7B6F3111Q38043522-F2B833D1-CFF6-488A-87FF-D09DFB4D91D7Q38044757-FDB013D8-33B8-4C7E-B559-D42C4710403AQ38071693-A359ACDA-45C2-40A1-961D-70DE727BF1FFQ38085662-4F4A277C-A915-46B8-8907-B91D5EA653A5Q38092899-C54E2C31-0CA4-4D2D-9B92-5B53007F0A20Q38102977-D3E48846-52A2-43B0-B042-249DBB6CA7FFQ38161412-A7BA6460-F7E4-44A8-B0D4-E1A5D5D97C62Q38167854-E0D7B563-AC68-46D0-9709-F54ACEAE8DFAQ38176004-88BEA5B0-D99B-44D9-BDD0-16F1827EB08AQ38180799-408545C5-EB39-4836-BB68-795CABF530CFQ38255582-3E88FD24-3D68-4DAA-B392-53DD5246D602Q38291356-8DB9ADB2-F858-4D0E-8444-ACB6FCDA208AQ38329024-BF4B1139-4202-4836-8BCB-BEACA0DE477DQ38395697-72E649C4-522E-4C01-9BF0-08FFDBA2C343Q38528889-FE285851-086E-40D7-A4EB-C60415F4548EQ38570721-02BBC009-4859-4536-A42F-AE94EE1FD8AEQ38597575-68BF35E2-9A41-4F3F-BF72-A7E4E6EB9FB6Q38613322-8F677D4A-0F2A-4D39-AD3C-00DE2279A394Q38633441-EB050B3E-ED61-49D8-9793-3B3F41C5AB31Q38814103-6DBC34CC-9DAB-415D-9CCD-3B09DF215B76
P2860
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A phase II, multicenter, open- ...... with active systemic features.
@ast
A phase II, multicenter, open- ...... with active systemic features.
@en
A phase II, multicenter, open- ...... with active systemic features.
@nl
type
label
A phase II, multicenter, open- ...... with active systemic features.
@ast
A phase II, multicenter, open- ...... with active systemic features.
@en
A phase II, multicenter, open- ...... with active systemic features.
@nl
prefLabel
A phase II, multicenter, open- ...... with active systemic features.
@ast
A phase II, multicenter, open- ...... with active systemic features.
@en
A phase II, multicenter, open- ...... with active systemic features.
@nl
P2093
P2860
P50
P356
P1476
A phase II, multicenter, open- ...... with active systemic features
@en
P2093
Abhijit Chakraborty
Alberto Martini
Andrea Chioato
Daniele D'Ambrosio
Emanuele Noseda
Jean Lecot
Nico Wulffraat
Nicolino Ruperto
Paediatric Rheumatology International Clinical Trials Organisation
Patricia Woo
P2860
P304
P356
10.1002/ART.33342
P577
2012-02-01T00:00:00Z